Hualu Network Group
中文版
search
Home Page
About us
Our Values
Development Milestone
News
News
Products
Product List for API
Recommended API
Product List for Finished Drug
Product list for Chemicals and Intermediates
Contract Manufacturing
API and Pharmaceutical Intermediates
OTC and Generics
Investor Relation
PERIODIC REPORT
INTERIM REPORT
INVESTORS SERVICE
Contact Us
Contact Us
Investor Relation
Information transparency and trust in peers
Investor Relation
PERIODIC REPORT
INTERIM REPORT
INVESTORS SERVICE
INTERIM REPORT
Home Page
/
Investor Relation
/
INTERIM REPORT
03
2026-08
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2026
02
2026-07
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2026
26
2026-06
Final Dividend For The Year Ended 31 December 2025
26
2026-06
Articles of Association
26
2026-06
(I) Poll Results of The Annual General Meeting; And (II)Payment of 2025 Final Dividend
22
2026-06
Overseas Regulatory Announcement-Announcement on Obtaining the Notice of Approval for Drug Clinical Trials
01
2026-06
Overseas Regulatory Announcement-Announcement on obtaining the Drug Registration Certificate for Sevelamer Carbonate for Suspension
01
2026-06
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2026
26
2026-05
Reply Slip for 2025 Annual General Meeting
26
2026-05
Proxy Form for 2025 Annual General Meeting
总条数:
87
条
＜
1
2
3
...
9
＞
跳转到:
页
跳转
Copyright © Shandong Xinhua Pharmaceutical Co., Ltd
鲁ICP备09066031号
鲁公安备案号 3703900200041
(鲁)-非经营性-2015-0068
Technical Support:CR DIGITAL
Xinhua Pharmaceutical
